Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.

PubWeight™: 2.42‹?› | Rank: Top 2%

🔗 View Article (PMID 15995960)

Published in J Infect Dis on June 23, 2005

Authors

Zabrina L Brumme1, James Goodrich, Howard B Mayer, Chanson J Brumme, Bethany M Henrick, Brian Wynhoven, Jerome J Asselin, Peter K Cheung, Robert S Hogg, Julio S G Montaner, P Richard Harrigan

Author Affiliations

1: BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, and Faculty of Medicine, University of British Columbia, Canada.

Articles citing this

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol (2006) 3.23

HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev (2008) 2.88

Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol (2007) 2.14

Predictors of disease progression in HIV infection: a review. AIDS Res Ther (2007) 2.05

Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis (2008) 2.01

Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol (2008) 1.81

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis (2010) 1.79

HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs (2012) 1.70

Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57

Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol (2008) 1.43

HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS (2009) 1.41

Plasma Metabolomics Biosignature According to HIV Stage of Infection, Pace of Disease Progression, Viremia Level and Immunological Response to Treatment. PLoS One (2016) 1.39

Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol (2006) 1.33

Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr (2009) 1.24

Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative. AIDS (2009) 1.18

Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults. Antimicrob Agents Chemother (2010) 1.16

Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med (2011) 1.15

Evolution of CCR5 use before and during coreceptor switching. J Virol (2008) 1.09

HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol (2013) 1.07

Clinical significance of HIV-1 coreceptor usage. J Transl Med (2011) 1.07

Hormonal contraception and HIV disease progression. Clin Infect Dis (2008) 1.06

Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr (2010) 1.04

Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays. Antimicrob Agents Chemother (2009) 1.04

HIV-1 pathogenesis: the virus. Cold Spring Harb Perspect Med (2012) 1.03

Tropism testing in the clinical management of HIV-1 infection. Curr Opin HIV AIDS (2009) 1.03

Characterization of partial and near full-length genomes of HIV-1 strains sampled from recently infected individuals in São Paulo, Brazil. PLoS One (2011) 1.02

R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch. J Virol (2008) 0.97

Maraviroc in the treatment of HIV infection. Drug Des Devel Ther (2009) 0.95

Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching. J Virol (2007) 0.93

Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals. AIDS Res Hum Retroviruses (2009) 0.92

Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review. AIDS (2014) 0.92

New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists. Ther Clin Risk Manag (2008) 0.91

Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage. Retrovirology (2011) 0.91

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS (2016) 0.91

HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners. Retrovirology (2013) 0.90

HIV-1 subtype and viral tropism determination for evaluating antiretroviral therapy options: an analysis of archived Kenyan blood samples. BMC Infect Dis (2009) 0.89

Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection. J Clin Microbiol (2010) 0.86

Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism. Antimicrob Agents Chemother (2008) 0.86

Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques. PLoS One (2011) 0.86

Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations. J Virol (2007) 0.86

Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure. Antimicrob Agents Chemother (2013) 0.85

The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. J Int AIDS Soc (2012) 0.85

Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers. AIDS Res Hum Retroviruses (2012) 0.84

The neuropathogenesis of feline immunodeficiency virus infection: barriers to overcome. Vet J (2010) 0.84

HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy. AIDS Res Hum Retroviruses (2006) 0.84

Bioinformatic analysis of HIV-1 entry and pathogenesis. Curr HIV Res (2014) 0.83

Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors. Antimicrob Agents Chemother (2009) 0.83

Prevalence and clinical associations of CXCR4-using HIV-1 among treatment-naive subtype C-infected women in Botswana. J Acquir Immune Defic Syndr (2011) 0.83

Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc. Clin Med Ther (2009) 0.83

Co-receptor usage and prediction of V3 genotyping algorithms in HIV-1 subtype B' from paid blood donors experienced anti-retroviral therapy in Chinese central province. Virol J (2010) 0.81

The temporal increase in HIV-1 non-R5 tropism frequency among newly diagnosed patients from northern Poland is associated with clustered transmissions. J Int AIDS Soc (2015) 0.81

HIV-1 drug resistance and resistance testing. Infect Genet Evol (2016) 0.80

Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques. Retrovirology (2012) 0.80

Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects. AIDS Res Hum Retroviruses (2013) 0.80

X4 viruses are frequently archived in patients with long-term HIV infection but do not seem to influence the "inflamm-aging" process. BMC Infect Dis (2013) 0.80

Critical amino acids within the human immunodeficiency virus type 1 envelope glycoprotein V4 N- and C-terminals contribute to virus entry. PLoS One (2014) 0.79

Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages. PLoS One (2013) 0.79

Analysis of the CCR5 gene coding region diversity in five South American populations reveals two new non-synonymous alleles in Amerindians and high CCR5*D32 frequency in Euro-Brazilians. Genet Mol Biol (2009) 0.79

Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains. J Transl Med (2015) 0.79

Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS. J Virol (2011) 0.79

Frequency of coreceptor tropism in PBMC samples from HIV-1 recently infected blood donors by massively parallel sequencing: the REDS II study. Virol J (2015) 0.78

Limited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapy. PLoS One (2014) 0.78

Predicted HIV-1 coreceptor usage among Kenya patients shows a high tendency for subtype d to be cxcr4 tropic. AIDS Res Ther (2012) 0.78

Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults. Can J Infect Dis Med Microbiol (2010) 0.78

Relevance of early detection of HIV type 1 SI/CXCR4-using viruses in vertically infected children. AIDS Res Hum Retroviruses (2011) 0.78

Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1. Virology (2010) 0.77

The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study. BMC Infect Dis (2014) 0.77

Determination of HIV-1 coreceptor tropism using proviral DNA in women before and after viral suppression. AIDS Res Ther (2015) 0.77

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients. HIV AIDS (Auckl) (2010) 0.77

Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. Open Forum Infect Dis (2014) 0.76

Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population. J Acquir Immune Defic Syndr (2014) 0.76

Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc. HIV AIDS (Auckl) (2010) 0.76

Association between HIV-1 coreceptor usage and resistance to broadly neutralizing antibodies. J Acquir Immune Defic Syndr (2014) 0.76

Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants. EBioMedicine (2016) 0.76

Differential evolution of a CXCR4-using HIV-1 strain in CCR5wt/wt and CCR5∆32/∆32 hosts revealed by longitudinal deep sequencing and phylogenetic reconstruction. Sci Rep (2015) 0.76

Peptide and protein-based inhibitors of HIV-1 co-receptors. Exp Biol Med (Maywood) (2013) 0.76

HIV-1 Epidemiology, Genetic Diversity, and Primary Drug Resistance in the Tyumen Oblast, Russia. Biomed Res Int (2016) 0.75

High-Sequence Diversity and Rapid Virus Turnover Contribute to Higher Rates of Coreceptor Switching in Treatment-Experienced Subjects with HIV-1 Viremia. AIDS Res Hum Retroviruses (2016) 0.75

A diagnostic HIV-1 tropism system based on sequence relatedness. J Clin Microbiol (2014) 0.75

Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection. Core Evid (2010) 0.75

Maraviroc: the evidence for its potential in the management of HIV. Core Evid (2007) 0.75

Non-R5-tropic HIV-1 in subtype A1 and D infections were associated with lower pretherapy CD4+ cell count but not with PI/(N)NRTI therapy outcomes in Mbarara, Uganda. AIDS (2016) 0.75

Deep Sequencing of the HIV-1 env Gene Reveals Discrete X4 Lineages and Linkage Disequilibrium between X4 and R5 Viruses in the V1/V2 and V3 Variable Regions. J Virol (2016) 0.75

Frequent detection of CXCR4-using viruses among Brazilian blood donors with HIV-1 long-standing infection and unknown clinical stage: Analysis of massive parallel sequencing data. Data Brief (2015) 0.75

HIV Co-receptor usage in HIV-related non-hodgkin's lymphoma. Infect Agent Cancer (2012) 0.75

The Pace of Co-receptor Tropism Switch in HIV-1 Infected Individuals after Recent Infection. J Virol (2017) 0.75

Articles by these authors

Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01

Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49

Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med (2008) 7.31

The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17

Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS (2002) 5.21

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00

Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med (2002) 4.77

Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68

Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55

The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54

Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46

Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ (2003) 4.38

Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74

Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72

Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS (2006) 3.70

The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67

Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction (2006) 3.65

Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J (2006) 3.49

Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med (2008) 3.48

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis (2010) 3.47

Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46

Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38

Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38

Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35

Influence of HLA-C expression level on HIV control. Science (2013) 3.27

Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J Virol (2008) 3.24

HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. J Virol (2008) 3.24

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17

Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet (2011) 3.14

Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12

The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Int J Drug Policy (2008) 3.05

Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health (2006) 3.04

Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (2007) 3.04

Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (2002) 2.99

Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med (2008) 2.97

Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93

Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81

Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78

Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA (2008) 2.77

Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS (2002) 2.74

Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74

Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr (2005) 2.74

Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction (2010) 2.65

Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ (2004) 2.63

Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ (2004) 2.62

A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61

Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis (2011) 2.60

Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS (2009) 2.55

Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther (2007) 2.49

When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis (2005) 2.48

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med (2007) 2.41

The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (2007) 2.39

Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33